Stocks
Barclays Sticks to Buy Rating on Eli Lilly & Co Despite Strong Quarter
Emily Field from Barclays has reaffirmed her Buy rating on Eli Lilly & Co (LLY), citing the company's strong quarterly earnings. In a report released today, she maintained a price target of $1,400.00.
Eli Lilly & Co recently reported revenue of $22.97 billion and a net profit of $7.1 billion for the quarter ending June 30, a significant increase from last year's revenue of $15.56 billion and net profit of $5.66 billion.
According to TipRanks, Field has an average return of 1.9% and a 45.77% success rate on recommended stocks. She covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and AbbVie.